156 related articles for article (PubMed ID: 28427157)
1. The anti-tumor efficacy of 3C23K, a glyco-engineered humanized anti-MISRII antibody, in an ovarian cancer model is mainly mediated by engagement of immune effector cells.
Estupina P; Fontayne A; Barret JM; Kersual N; Dubreuil O; Le Blay M; Pichard A; Jarlier M; Pugnière M; Chauvin M; Chardès T; Pouget JP; Deshayes E; Rossignol A; Abache T; de Romeuf C; Terrier A; Verhaeghe L; Gaucher C; Prost JF; Pèlegrin A; Navarro-Teulon I
Oncotarget; 2017 Jun; 8(23):37061-37079. PubMed ID: 28427157
[TBL] [Abstract][Full Text] [Related]
2. Increasing FcγRIIa affinity of an FcγRIII-optimized anti-EGFR antibody restores neutrophil-mediated cytotoxicity.
Derer S; Glorius P; Schlaeth M; Lohse S; Klausz K; Muchhal U; Desjarlais JR; Humpe A; Valerius T; Peipp M
MAbs; 2014; 6(2):409-21. PubMed ID: 24492248
[TBL] [Abstract][Full Text] [Related]
3. Glycoengineered Pichia produced anti-HER2 is comparable to trastuzumab in preclinical study.
Zhang N; Liu L; Dumitru CD; Cummings NR; Cukan M; Jiang Y; Li Y; Li F; Mitchell T; Mallem MR; Ou Y; Patel RN; Vo K; Wang H; Burnina I; Choi BK; Huber HE; Stadheim TA; Zha D
MAbs; 2011; 3(3):289-98. PubMed ID: 21487242
[TBL] [Abstract][Full Text] [Related]
4. A novel Fc-engineered cathepsin D-targeting antibody enhances ADCC, triggers tumor-infiltrating NK cell recruitment, and improves treatment with paclitaxel and enzalutamide in triple-negative breast cancer.
Desroys du Roure P; Lajoie L; Mallavialle A; Alcaraz LB; Mansouri H; Fenou L; Garambois V; Rubio L; David T; Coenon L; Boissière-Michot F; Chateau MC; Ngo G; Jarlier M; Villalba M; Martineau P; Laurent-Matha V; Roger P; Guiu S; Chardès T; Gros L; Liaudet-Coopman E
J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38290768
[TBL] [Abstract][Full Text] [Related]
5. Preclinical characterization of a novel investigational monoclonal antibody CM313 with potent CD38-positive cell killing activity.
Liu W; Yu J; Sun K; Song Q; Li Y; He Y; Wang Y; Xu G; Wang C; Chen B
Front Immunol; 2024; 15():1410457. PubMed ID: 38765013
[TBL] [Abstract][Full Text] [Related]
6. Binding Affinity, Specificity and Comparative Biodistribution of the Parental Murine Monoclonal Antibody MX35 (Anti-NaPi2b) and Its Humanized Version Rebmab200.
Lindegren S; Andrade LN; Bäck T; Machado CM; Horta BB; Buchpiguel C; Moro AM; Okamoto OK; Jacobsson L; Cederkrantz E; Washiyama K; Aneheim E; Palm S; Jensen H; Tuma MC; Chammas R; Hultborn R; Albertsson P
PLoS One; 2015; 10(5):e0126298. PubMed ID: 25970341
[TBL] [Abstract][Full Text] [Related]
7. Role of IgE receptors in IgE antibody-dependent cytotoxicity and phagocytosis of ovarian tumor cells by human monocytic cells.
Karagiannis SN; Bracher MG; Beavil RL; Beavil AJ; Hunt J; McCloskey N; Thompson RG; East N; Burke F; Sutton BJ; Dombrowicz D; Balkwill FR; Gould HJ
Cancer Immunol Immunother; 2008 Feb; 57(2):247-63. PubMed ID: 17657488
[TBL] [Abstract][Full Text] [Related]
8. Fully human antagonistic antibodies against CCR4 potently inhibit cell signaling and chemotaxis.
Hagemann UB; Gunnarsson L; Géraudie S; Scheffler U; Griep RA; Reiersen H; Duncan AR; Kiprijanov SM
PLoS One; 2014; 9(7):e103776. PubMed ID: 25080123
[TBL] [Abstract][Full Text] [Related]
9. Exchanging human Fcgamma1 with murine Fcgamma2a highly potentiates anti-tumor activity of anti-EpCAM antibody adecatumumab in a syngeneic mouse lung metastasis model.
Lutterbuese P; Brischwein K; Hofmeister R; Crommer S; Lorenczewski G; Petersen L; Lippold S; da Silva A; Locher M; Baeuerle PA; Schlereth B
Cancer Immunol Immunother; 2007 Apr; 56(4):459-68. PubMed ID: 16937114
[TBL] [Abstract][Full Text] [Related]
10. The novel high-affinity humanized antibody IMM40H targets CD70, eliminates tumors via Fc-mediated effector functions, and interrupts CD70/CD27 signaling.
Li S; Chen D; Guo H; Liu D; Yang C; Zhang R; Wang T; Zhang F; Bai X; Yang Y; Sun N; Zhang W; Zhang L; Zhao G; Peng L; Tu X; Tian W
Front Oncol; 2023; 13():1240061. PubMed ID: 37849799
[TBL] [Abstract][Full Text] [Related]
11. A novel Fc-enhanced humanized monoclonal antibody targeting B7-H3 suppresses the growth of ESCC.
Wu H; Liu C; Yuan Q; Qiao Y; Ding Y; Duan L; Li W; Zhang M; Zhang X; Jiang Y; Lu J; Dong Z; Wang T; Liu K; Zhao J
Oncoimmunology; 2023; 12(1):2282250. PubMed ID: 38126034
[TBL] [Abstract][Full Text] [Related]
12. Cell-based production of Fc-GlcNAc and Fc-alpha-2,6 sialyl glycan enriched antibody with improved effector functions through glycosylation pathway engineering.
Huang HW; Shivatare VS; Tseng TH; Wong CH
bioRxiv; 2023 Dec; ():. PubMed ID: 38187613
[TBL] [Abstract][Full Text] [Related]
13. Expression of CD40 and growth-inhibitory activity of CD40 agonist in ovarian carcinoma cells.
Zhou Y; He J; Gou LT; Mu B; Liao WC; Ma C; Tang P; Zhou SJ; Zhou YJ; Yang JL
Cancer Immunol Immunother; 2012 Oct; 61(10):1735-43. PubMed ID: 22406982
[TBL] [Abstract][Full Text] [Related]
14. IMM47, a humanized monoclonal antibody that targets CD24, exhibits exceptional anti-tumor efficacy by blocking the CD24/Siglec-10 interaction and can be used as monotherapy or in combination with anti-PD1 antibodies for cancer immunotherapy.
Li S; Chen D; Guo H; Yang Y; Liu D; Yang C; Bai X; Zhang W; Zhang L; Zhao G; Tu X; Peng L; Liu S; Song Y; Jiang Z; Zhang R; Yu J; Tian W
Antib Ther; 2023 Oct; 6(4):240-252. PubMed ID: 37846296
[TBL] [Abstract][Full Text] [Related]
15. Elucidating the development, characterization, and antitumor potential of a novel humanized antibody against Trop2.
Zhou DD; Sun LP; Yu Q; Zhai XT; Zhang LW; Gao RJ; Zhen YS; Wang R; Miao QF
Int J Biol Macromol; 2023 Dec; 253(Pt 6):127105. PubMed ID: 37769779
[TBL] [Abstract][Full Text] [Related]
16. Downregulation of neuropilin-1 on macrophages modulates antibody-mediated tumoricidal activity.
Kawaguchi K; Suzuki E; Nishie M; Kii I; Kataoka TR; Hirata M; Inoue M; Pu F; Iwaisako K; Tsuda M; Yamaguchi A; Haga H; Hagiwara M; Toi M
Cancer Immunol Immunother; 2017 Sep; 66(9):1131-1142. PubMed ID: 28432397
[TBL] [Abstract][Full Text] [Related]
17. FcγRIIB Is an Immune Checkpoint Limiting the Activity of Treg-Targeting Antibodies in the Tumor Microenvironment.
Knorr DA; Blanchard L; Leidner RS; Jensen SM; Meng R; Jones A; Ballesteros-Merino C; Bell RB; Baez M; Marino A; Sprott D; Bifulco CB; Piening B; Dahan R; Osorio JC; Fox BA; Ravetch JV
Cancer Immunol Res; 2024 Mar; 12(3):322-333. PubMed ID: 38147316
[TBL] [Abstract][Full Text] [Related]
18. Macrophage N-glycan processing inhibits antibody-dependent cellular phagocytosis.
Díaz de León JSA; Aguilar I; Barb AW
Glycobiology; 2023 Dec; 33(12):1182-1192. PubMed ID: 37792857
[TBL] [Abstract][Full Text] [Related]
19. The novel drug candidate S2/IAPinh improves survival in models of pancreatic and ovarian cancer.
Hagi T; Vangveravong S; Takchi R; Gong Q; Goedegebuure SP; Tiriac H; Van Tine BA; Powell MA; Hawkins WG; Spitzer D
Sci Rep; 2024 Mar; 14(1):6373. PubMed ID: 38493257
[TBL] [Abstract][Full Text] [Related]
20. A novel Fc-engineered human ICAM-1/CD54 antibody with potent anti-myeloma activity developed by cellular panning of phage display libraries.
Klausz K; Cieker M; Kellner C; Oberg HH; Kabelitz D; Valerius T; Burger R; Gramatzki M; Peipp M
Oncotarget; 2017 Sep; 8(44):77552-77566. PubMed ID: 29100408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
